Markers of and risk factors for the development and progression of diabetic kidney disease

American Journal of Kidney Diseases

Volumn 63, Issue 2 SUPPL.2, 2014, Pages

  Macisaac, Richard J ^a   Ekinci, Elif I ^a,b,c   Jerums, George ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

biomarker; Diabetes mellitus; disease trajectory; end stage renal disease (ESRD); risk factor

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; CONNECTIVE TISSUE GROWTH FACTOR; CYSTATIN C; FATTY ACID BINDING PROTEIN; FIBROBLAST GROWTH FACTOR 23; KIDNEY INJURY MOLECULE 1; LIPID; MATRIX PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; URIC ACID;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE; DIABETIC NEPHROPATHY; DISEASE COURSE; DYSLIPIDEMIA; FAMILY HISTORY; GENETIC MARKER; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY SIZE; LIPID BLOOD LEVEL; MICROALBUMINURIA; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN GLYCOSYLATION; PROTEOMICS; REMISSION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SMOKING; ULTRAFILTRATION; URIC ACID BLOOD LEVEL;

BIOMARKER; DIABETES MELLITUS; DISEASE TRAJECTORY; END-STAGE RENAL DISEASE (ESRD); RISK FACTOR;

BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; PROGNOSIS; RISK FACTORS;

EID: 84892905009     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.10.048     Document Type: Article

References (131)

1. P.H. Groop, M.C. Thomas, and J.L. Moran et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes Diabetes 58 7 2009 1651 1658
2. T.J. Orchard, A.M. Secrest, R.G. Miller, and T. Costacou In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study Diabetologia 53 11 2010 2312 2319
3. E. Barkoudah, H. Skali, H. Uno, S.D. Solomon, and M.A. Pfeffer Mortality rates in trials of subjects with type 2 diabetes J Am Heart Assoc 1 1 2012 8 15
4. M. Tonelli, P. Muntner, and A. Lloyd et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study Lancet 380 9844 2012 807 814
5. R.J. MacIsaac, and G. Jerums Diabetic kidney disease with and without albuminuria Curr Opin Nephrol Hypertens 20 3 2011 246 257
6. A.S. Levey, P.E. de Jong, and J. Coresh et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report Kidney Int 80 1 2011 17 28
7. B.A. Perkins, and A.S. Krolewski Early nephropathy in type 1 diabetes: the importance of early renal function decline Curr Opin Nephrol Hypertens 18 3 2009 233 240
8. G. Jerums, E. Premaratne, S. Panagiotopoulos, and R.J. MacIsaac The clinical significance of hyperfiltration in diabetes Diabetologia 53 10 2010 2093 2104
9. J. Skupien, J.H. Warram, and A.M. Smiles et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease Kidney Int 82 5 2012 589 597
10. R. Retnakaran, C.A. Cull, K.I. Thorne, A.I. Adler, R.R. Holman Group US Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74 Diabetes 55 6 2006 1832 1839 (Pubitemid 44324140)
11. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 6865 2001 813 820 (Pubitemid 34000785)
12. M.J. Sheetz, and G.L. King Molecular understanding of hyperglycemia's adverse effects for diabetic complications JAMA 288 20 2002 2579 2588 (Pubitemid 35386893)
13. M.E. Cooper Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy Diabetologia 44 11 2001 1957 1972 (Pubitemid 33124041)
14. I.M. Stratton, A.I. Adler, and H.A. Neil et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 7258 2000 405 412 (Pubitemid 30609442)
15. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 329 14 1993 977 986
16. 1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds Diabetologia 55 3 2012 636 643
17. DCCT EDIC Research Group I.H. de Boer, W. Sun, and P.A. Cleary et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes N Engl J Med 365 25 2011 2366 2376
18. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 9131 1998 837 853
19. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-Year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 15 2008 1577 1589
20. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes [published online ahead of print March 20, 2013]. Kidney Int. http://dx.doi.org/10.1038/ki.2012. 401.
21. 1c reduces risk of end-stage renal disease in patients with type 1 diabetes and proteinuria J Am Soc Nephrol 23 suppl 2012 1163
22. S.G. Coca, F. Ismail-Beigi, N. Haq, H.M. Krumholz, and C.R. Parikh Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes Arch Intern Med 172 10 2012 761 769
23. P. Fioretto, M.W. Steffes, D.E. Sutherland, F.C. Goetz, and M. Mauer Reversal of lesions of diabetic nephropathy after pancreas transplantation N Engl J Med 339 2 1998 69 75 (Pubitemid 28304880)
24. B.I. Freedman, M. Bostrom, P. Daeihagh, and D.W. Bowden Genetic factors in diabetic nephropathy Clin J Am Soc Nephrol 2 6 2007 1306 1316
25. M.C. Thomas, P.H. Groop, and K. Tryggvason Towards understanding the inherited susceptibility for nephropathy in diabetes Curr Opin Nephrol Hypertens 21 2 2012 195 202
26. A.J. Bleyer, J.R. Sedor, and B.I. Freedman et al. Risk factors for development and progression of diabetic kidney disease and treatment patterns among diabetic siblings of patients with diabetic kidney disease Am J Kidney Dis 51 1 2008 29 37 (Pubitemid 350296526)
27. Z.Y. Yu, L.S. Chen, L.C. Zhang, and T.B. Zhou Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy Nephrology (Carlton) 17 5 2012 480 487
28. A.S. Krolewski, G.D. Poznik, and G. Placha et al. A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes Kidney Int 69 1 2006 129 136 (Pubitemid 43117748)
29. M.G. Pezzolesi, P. Katavetin, and M. Kure et al. Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy Diabetes 58 11 2009 2698 2702
30. S. Tonna, A. El-Osta, M.E. Cooper, and C. Tikellis Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms Nat Rev Nephrol 6 6 2010 332 341
31. C. Sapienza, J. Lee, and J. Powell et al. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy Epigenetics 6 1 2011 20 28
32. G. Riviere, D. Lienhard, T. Andrieu, D. Vieau, B.M. Frey, and F.J. Frey Epigenetic regulation of somatic angiotensin-converting enzyme by DNA methylation and histone acetylation Epigenetics 6 4 2011 478 489
33. G.M. Magee, R.W. Bilous, C.R. Cardwell, S.J. Hunter, F. Kee, and D.G. Fogarty Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis Diabetologia 52 4 2009 691 697
34. L.H. Ficociello, B.A. Perkins, and B. Roshan et al. Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes Diabetes Care 32 5 2009 889 893
35. M.E. Pavkov, W.C. Knowler, K.V. Lemley, C.C. Mason, B.D. Myers, and R.G. Nelson Early renal function decline in type 2 diabetes Clin J Am Soc Nephrol 7 1 2012 78 84
36. P. Ruggenenti, E.L. Porrini, and F. Gaspari et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes Diabetes Care 35 10 2012 2061 2068
37. R.D. Lindeman, J. Tobin, and N.W. Shock Longitudinal studies on the rate of decline in renal function with age J Am Geriatr Soc 33 4 1985 278 285 (Pubitemid 15087125)
38. B.A. Perkins, L.H. Ficociello, and B.E. Ostrander et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes J Am Soc Nephrol 18 4 2007 1353 1361 (Pubitemid 46536923)
39. M.E. Molitch, M. Steffes, and W. Sun et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study Diabetes Care 33 7 2010 1536 1543
40. M.L. Caramori, P. Fioretto, and M. Mauer The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 49 9 2000 1399 1408
41. P. Gaede, L. Tarnow, P. Vedel, H.H. Parving, and O. Pedersen Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria Nephrol Dial Transplant 19 11 2004 2784 2788 (Pubitemid 39480973)
42. M.E. Hellemons, F. Persson, and S.J. Bakker et al. Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial Diabetes Care 34 9 2011 2078 2083
43. G. Jerums, S. Panagiotopoulos, E. Premaratne, D.A. Power, and R.J. MacIsaac Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: a pooled analysis Am J Nephrol 28 4 2008 614 627 (Pubitemid 351832449)
44. T. Babazono, I. Nyumura, and K. Toya et al. Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients Diabetes Care 32 8 2009 1518 1520
45. D.J. Newman, M.B. Mattock, and A.B. Dawnay et al. Systematic review on urine albumin testing for early detection of diabetic complications Health Technol Assess 9 30 2005 iii vi xiii-163
46. M.D. Flather, M.E. Farkouh, J.M. Pogue, and S. Yusuf Strengths and limitations of meta-analysis: larger studies may be more reliable Control Clin Trials 18 6 1997 568 579 discussion 661-666 (Pubitemid 27521695)
47. W.D. Comper, T.M. Osicka, M. Clark, R.J. MacIsaac, and G. Jerums Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay Kidney Int 65 5 2004 1850 1855 (Pubitemid 38591035)
48. J.W. Brinkman, S.J. Bakker, and R.T. Gansevoort et al. Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC Kidney Int Suppl 92 2004 S69 S75
49. K.R. Polkinghorne, Q. Su, S.J. Chadban, J.E. Shaw, P.Z. Zimmet, and R.C. Atkins Population prevalence of albuminuria in the Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study: immunonephelometry compared with high-performance liquid chromatography Am J Kidney Dis 47 4 2006 604 613
50. B.A. Perkins, L.H. Ficociello, B. Roshan, J.H. Warram, and A.S. Krolewski In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria Kidney Int 77 1 2010 57 64
51. P.H. Lane, M.W. Steffes, and S.M. Mauer Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion Diabetes 41 5 1992 581 586
52. C. Tsalamandris, T.J. Allen, and R.E. Gilbert et al. Progressive decline in renal function in diabetic patients with and without albuminuria Diabetes 43 5 1994 649 655 (Pubitemid 24138777)
53. H.J. Kramer, Q.D. Nguyen, G. Curhan, and C.Y. Hsu Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus JAMA 289 24 2003 3273 3277 (Pubitemid 37430080)
54. R.J. MacIsaac, C. Tsalamandris, S. Panagiotopoulos, T.J. Smith, K.J. McNeil, and G. Jerums Nonalbuminuric renal insufficiency in type 2 diabetes Diabetes Care 27 1 2004 195 200 (Pubitemid 38196732)
55. ACCORD Study Group W.C. Cushman, G.W. Evans, and R.P. Byington et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 17 2010 1575 1585
56. R.M. Cooper-DeHoff, Y. Gong, and E.M. Handberg et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease JAMA 304 1 2010 61 68
57. American Diabetes Association Summary of revisions for the 2013 clinical practice recommendations Diabetes Care 36 suppl 1 2013 S1 S110
58. E. Lurbe, J. Redon, and A. Kesani et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes N Engl J Med 347 11 2002 797 805 (Pubitemid 34988338)
59. N.D. Sturrock, E. George, N. Pound, J. Stevenson, G.M. Peck, and H. Sowter Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus Diabet Med 17 5 2000 360 364 (Pubitemid 30353800)
60. R. Agarwal, and M.J. Andersen Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease Kidney Int 69 7 2006 1175 1180
61. C.R. Cardoso, N.C. Leite, E.S. Muxfeldt, and G.F. Salles Thresholds of ambulatory blood pressure associated with chronic complications in type 2 diabetes Am J Hypertens 25 1 2012 82 88
62. J. Morton, S. Zoungas, and Q. Li et al. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE Study Diabetes Care 35 11 2012 2201 2206
63. A.J. Jenkins, T.J. Lyons, and D. Zheng et al. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy Kidney Int 64 3 2003 817 828 (Pubitemid 37013817)
64. L.H. Ficociello, B.A. Perkins, and K.H. Silva et al. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors Clin J Am Soc Nephrol 2 3 2007 461 469
65. N. Tolonen, C. Forsblom, and L. Thorn et al. Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes Diabetologia 52 12 2009 2522 2530
66. J. Shepherd, J.J. Kastelein, and V. Bittner et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) Study Clin J Am Soc Nephrol 2 6 2007 1131 1139
67. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) Am J Kidney Dis 54 5 2009 810 819
68. V. Rigalleau, M. Garcia, and C. Lasseur et al. Large kidneys predict poor renal outcome in subjects with diabetes and chronic kidney disease BMC Nephrol 11 2010 3
69. G. Zerbini, R. Bonfanti, and F. Meschi et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes Diabetes 55 9 2006 2620 2625 (Pubitemid 44871164)
70. M.J. Lee, D. Feliers, and M.M. Mariappan et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy Am J Physiol Renal Physiol 292 2 2007 F617 F627
71. T.W. Tervaert, A.L. Mooyaart, and K. Amann et al. Pathologic classification of diabetic nephropathy J Am Soc Nephrol 21 4 2010 556 563
72. M.L. Caramori, Y. Kim, and C. Huang et al. Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes Diabetes 51 2 2002 506 513 (Pubitemid 34764810)
73. P. Fioretto, M. Mauer, and E. Brocco et al. Patterns of renal injury in NIDDM patients with microalbuminuria Diabetologia 39 12 1996 1569 1576 (Pubitemid 26397369)
74. T. Okada, T. Nagao, H. Matsumoto, Y. Nagaoka, T. Wada, and T. Nakao Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria Nephrology (Carlton) 17 1 2012 68 75
75. R.J. MacIsaac, S. Panagiotopoulos, and K.J. McNeil et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 29 7 2006 1560 1566 (Pubitemid 44127581)
76. R. Nosadini, M. Velussi, and E. Brocco et al. Increased renal arterial resistance predicts the course of renal function in type 2 diabetes with microalbuminuria Diabetes 55 1 2006 234 239 (Pubitemid 43343320)
77. P.M. Srivastava, P. Calafiore, and R.J. MacIsaac et al. Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with type 2 diabetes Clin Sci (Lond) 114 4 2008 313 320 (Pubitemid 351294007)
78. R. Bouchi, T. Babazono, and M. Mugishima et al. Arterial stiffness is associated with incident albuminuria and decreased glomerular filtration rate in type 2 diabetic patients Diabetes Care 34 12 2011 2570 2575
79. T. Uzu, Y. Kida, and N. Shirahashi et al. Cerebral microvascular disease predicts renal failure in type 2 diabetes J Am Soc Nephrol 21 3 2010 520 526
80. K. Hanai, T. Babazono, and I. Nyumura et al. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes Nephrol Dial Transplant 24 6 2009 1884 1888
81. F. Persson, P. Rossing, and P. Hovind et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) study Scand J Clin Lab Invest 68 8 2008 731 738
82. M.C. Thomas, C. Tsalamandris, and R. MacIsaac et al. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes Kidney Int 66 3 2004 1167 1172 (Pubitemid 39121024)
83. S.A. Penfold, M.T. Coughlan, and S.K. Patel et al. Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy Kidney Int 78 3 2010 287 295
84. Y. Yamamoto, I. Kato, and T. Doi et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice J Clin Invest 108 2 2001 261 268 (Pubitemid 32656250)
85. B.A. Perkins, N. Rabbani, and A. Weston et al. Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes PLoS One 7 4 2012 e35655
86. M.T. Coughlan, S.K. Patel, and G. Jerums et al. Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man Am J Nephrol 34 4 2011 347 355
87. P.P. Wolkow, M.A. Niewczas, and B. Perkins et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics J Am Soc Nephrol 19 4 2008 789 797
88. M.A. Niewczas, L.H. Ficociello, and A.C. Johnson et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes Clin J Am Soc Nephrol 4 1 2009 62 70
89. M.A. Niewczas, T. Gohda, and J. Skupien et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes J Am Soc Nephrol 23 3 2012 507 515
90. T. Gohda, M.A. Niewczas, and L.H. Ficociello et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes J Am Soc Nephrol 23 3 2012 516 524
91. M.F. Lopes-Virella, N.L. Baker, and K.J. Hunt et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects Diabetes Care 36 8 2013 2317 2323
92. M. Sedeek, A.C. Montezano, and R.L. Hebert et al. Oxidative stress, Nox isoforms and complications of diabetes - potential targets for novel therapies J Cardiovasc Transl Res 5 4 2012 509 518
93. Y. Hinokio, S. Suzuki, M. Hirai, C. Suzuki, M. Suzuki, and T. Toyota Urinary excretion of 8-oxo-7, 8-dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathy Diabetologia 45 6 2002 877 882
94. M. Serdar, E. Sertoglu, and M. Uyanik et al. Comparison of 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels using mass spectrometer and urine albumin creatinine ratio as a predictor of development of diabetic nephropathy Free Radic Res 46 10 2012 1291 1295
95. M.A. Riojas, R.E. Villanueva-Vedia, and R. Zamilpa et al. Prevalence of diabetes mellitus and correlation of urinary transforming growth factor-beta1 with blood hemoglobin A1C in the Atascosa Diabetes Study Ethn Dis 18 2 suppl 2 2008 54 59
96. M.J. Kim, A.H. Frankel, and M. Donaldson et al. Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition Kidney Int 80 8 2011 851 860
97. R.E. Gilbert, A. Akdeniz, and S. Weitz et al. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy Diabetes Care 26 9 2003 2632 2636 (Pubitemid 37052112)
98. T.Q. Nguyen, L. Tarnow, and S. Andersen et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy Diabetes Care 29 1 2006 83 88 (Pubitemid 44033436)
99. T.Q. Nguyen, L. Tarnow, and A. Jorsal et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy Diabetes Care 31 6 2008 1177 1182
100. S.K. Patel, B. Wai, and R.J. Macisaac et al. The CTGF gene-945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes Cardiovasc Diabetol 11 2012 42
101. A. Dendooven, T.Q. Nguyen, and L. Brosens et al. The CTGF-945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes J Negat Results Biomed 10 2011 4
102. A. Grubb, O. Simonsen, G. Sturfelt, L. Truedsson, and H. Thysell Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate Acta Med Scand 218 5 1985 499 503 (Pubitemid 16147646)
103. R.J. MacIsaac, E. Premaratne, and G. Jerums Estimating glomerular filtration rate in diabetes using serum cystatin C Clin Biochem Rev 32 2 2011 61 67
104. B.A. Perkins, R.G. Nelson, and B.E. Ostrander et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study J Am Soc Nephrol 16 5 2005 1404 1412 (Pubitemid 41716524)
105. E. Premaratne, R.J. MacIsaac, S. Finch, S. Panagiotopoulos, E. Ekinci, and G. Jerums Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes Diabetes Care 31 5 2008 971 973
106. A.S. Krolewski, J.H. Warram, and C. Forsblom et al. Serum concentration of cystatin C and risk of end-stage renal disease in diabetes Diabetes Care 35 11 2012 2311 2316
107. M.E. Pavkov, W.C. Knowler, and R.L. Hanson et al. Comparison of serum cystatin C, serum creatinine, measured GFR, and estimated GFR to assess the risk of kidney failure in American Indians with diabetic nephropathy Am J Kidney Dis 62 1 2013 33 41
108. R.E. Gilbert, and M.E. Cooper The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56 5 1999 1627 1637 (Pubitemid 29518163)
109. S.E. Nielsen, S. Andersen, D. Zdunek, G. Hess, H.H. Parving, and P. Rossing Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy Kidney Int 79 10 2011 1113 1118
110. B.R. Conway, D. Manoharan, and D. Manoharan et al. Measuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factors Kidney Int 82 7 2012 812 818
111. A. Kamijo-Ikemori, T. Sugaya, and T. Yasuda et al. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients Diabetes Care 34 3 2011 691 696
112. F.L. Nauta, W.E. Boertien, and S.J. Bakker et al. Glomerular and tubular damage markers are elevated in patients with diabetes Diabetes Care 34 4 2011 975 981
113. S.E. Nielsen, T. Sugaya, P. Hovind, T. Baba, H.H. Parving, and P. Rossing Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients Diabetes Care 33 6 2010 1320 1324
114. S.S. Kim, S.H. Song, and I.J. Kim et al. Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy Diabetes Care 36 3 2013 656 661
115. E.T. Rosolowsky, L.H. Ficociello, and N.J. Maselli et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes Clin J Am Soc Nephrol 3 3 2008 706 713
116. L.H. Ficociello, E.T. Rosolowsky, and M.A. Niewczas et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up Diabetes Care 33 6 2010 1337 1343
117. P. Hovind, P. Rossing, L. Tarnow, R.J. Johnson, and H.H. Parving Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study Diabetes 58 7 2009 1668 1671
118. D.I. Jalal, C.J. Rivard, and R.J. Johnson et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes Study Nephrol Dial Transplant 25 6 2010 1865 1869
119. G. Zoppini, G. Targher, and M. Chonchol et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function Diabetes Care 35 1 2012 99 104
120. Y. Miao, S.A. Ottenbros, and G.D. Laverman et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial Hypertension 58 1 2011 2 7
121. D.M. Maahs, L. Caramori, and D.Z. Cherney et al. Uric acid lowering to prevent kidney function loss in diabetes: the Preventing Early Renal Function Loss (PERL) allopurinol study Curr Diab Rep 13 4 2013 550 559
122. M.L. Merchant, B.A. Perkins, and G.M. Boratyn et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria J Am Soc Nephrol 20 9 2009 2065 2074
123. D.M. Maahs, J. Siwy, and A. Argiles et al. Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology PLoS One 5 9 2010 e13051
124. D.M. Good, P. Zurbig, and A. Argiles et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease Mol Cell Proteomics 9 11 2010 2424 2437
125. P. Zurbig, G. Jerums, and P. Hovind et al. Urinary proteomics for early diagnosis in diabetic nephropathy Diabetes 61 12 2012 3304 3313
126. S.S. Roscioni, D. de Zeeuw, and M.E. Hellemons et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus Diabetologia 56 2 2013 259 267
127. S.M. Titan, R. Zatz, and F.G. Graciolli et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy Clin J Am Soc Nephrol 6 2 2011 241 247
128. S. Araki, M. Haneda, and D. Koya et al. Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria Diabetes Care 33 8 2010 1805 1810
129. T. Nakamura, C. Ushiyama, and S. Suzuki et al. Urinary excretion of podocytes in patients with diabetic nephropathy Nephrol Dial Transplant 15 9 2000 1379 1383
130. M. Zheng, L.L. Lv, and J. Ni et al. Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy PLoS One 6 5 2011 e20431
131. S. Putta, L. Lanting, G. Sun, G. Lawson, M. Kato, and R. Natarajan Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy J Am Soc Nephrol 23 3 2012 458 469